Follow on Google News News By Tag * Pharmaceutical * Healthcare * Drug * Roche * Medicines * Generic * Novartis * Disease * Us721 * Lowered * More Tags... Industry News News By Place Country(s) Industry News
Follow on Google News | Recently released market study: Switzerland Pharmaceuticals & Healthcare Report Q3 2011Fast Market Research recommends "Switzerland Pharmaceuticals & Healthcare Report Q3 2011" from Business Monitor International, now available
Headline Expenditure Projections * Pharmaceuticals: * Healthcare: * Medical devices: CHF5.15bn (US$4.90bn) in 2010 to CHF5.27bn (US$5.73bn) in 2011; 2.3% growth in local currency terms and 16.9% in US dollar terms. Our forecast has been revised moderately due to analyst intervention. ------------------------------------------------------------ Full Report Details at - http://www.fastmr.com/ ------------------------------------------------------------ Business Environment Rating: In BMI's Western Europe Business Environment Ratings for Q311, Switzerland is ranked second, above Germany. Switzerland's score for the quarter stands at 70.1, well above the regional average of 64.4. Globally, the country is ranked in third position, however, BMI anticipates that Switzerland may fall down the world rankings in the medium to long term as large, highgrowth emerging markets such as Brazil and China become more alluring to multinational drugmakers. This is especially pertinent in the wake of the government's increasingly cautious attitude to spending, which has resulted in the implementation of cost-containment measures such as drug price cuts. Key Trends & Developments * In May 2011 it was revealed that Japan's largest drugmaker, Takeda Pharmaceutical, is to acquire privately-held Swiss pharmaceutical company Nycomed for US$13.7bn - Takeda's second major buy after its US$8.8bn purchase of Millennium Pharmaceuticals in 2008. Nycomed will be turned into a wholly-owned unit after Takeda finalises the purchase of shares from a consortium of private equity funds including Nordic Capital and DLJ Merchant Banking, an affiliate of Credit Suisse Group. * In May 2011, German pharmaceutical company Stada announced that it had entered concrete negotiations with Switzerland's Spirig Pharma AG about the acquisition of Spirig's generic drugs business in Switzerland. The portfolio in focus will include 56 prescription and 15 non prescription drugs with an estimated annual sales volume of CHF45mn. However, the acquisition would not include any production facilities. A final decision on the acquisition is expected within the next three months. Stada is seeking to reduce its dependence on the German generic drug market. BMI Economic View: Switzerland's economy will see continued expansion through the quarters ahead, driven by robust private consumption and firm external demand for Swiss exports. Indeed, despite global headwinds in the form of the March 11 Japanese earthquake and the political crisis in Libya, we have revised up our forecast for Swiss growth in 2011 from 1.8% to 1.9%, on account of the continued resilience of the Swiss export sector in the face of the considerable strengthening of the franc over the past 12 months. BMI Political View: Switzerland's high short- and long-term political risk ratings reflect the broad-based political consensus within the country, which ensures a high degree of policy continuity and stability. A system of referenda to change the constitution and laws (by request) ensures a high degree of involvement for the population in political affairs, which maintains trust in the system. In addition, despite the existence of several linguistic groups, social stability is among the best in the world, with unrest extremely rare. Switzerland's relative independence from multilateral organisations leaves the government largely free to act, while it has no major disputes with neighbours. About Business Monitor International Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets. BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports. Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports. View more research from Business Monitor International at http://www.fastmr.com/ About Fast Market Research Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156. # # # Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available. End
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number